



Supplementary Figure 2. On-natalizumab disease activity during the first 2 years of analysis in each patient subset, shown as cumulative probability of (a) relapse, (b) 24-week–confirmed disability worsening, and (c) 24-week–confirmed disability improvement.





CI: confidence interval; HR: hazard ratio.